Tencent’s We Doctor Partners with CHA on National Digital Health Platform and Academic Initiatives
We Doctor, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700) specializing...
Fineline Cube
Huadong Medicine Secures Exclusive Rights to Janagliflozin for Type 2 Diabetes Treatment in China
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing...
Beijing Aims to Establish Rare Disease Drug Security Pilot Zone with ‘White List’ System
Beijing is set to follow in the footsteps of Boao Lecheng with the release of...
Beijing Authorities Release Negative List for Data Export in Key Industries
Authorities in Beijing, including the Beijing Municipal Bureau of Commerce and the Beijing Municipal Service...
AstraZeneca’s HIMALAYA Trial Data Showcases Significant Survival Benefits for Liver Cancer Treatment at ESMO 2024
At the European Society for Medical Oncology (ESMO) 2024 conference, AstraZeneca (NASDAQ: AZN, LON: AZN)...
Aligos Therapeutics’ ALG-055009 Achieves Positive Topline Results in Phase 2a HERALD Study for MASH
Aligos Therapeutics, a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive...
Roche’s Xofluza Receives FDA Approval for Reducing Influenza Transmission in Phase III Study
Roche (SWX: ROG; OTCMKTS: RHHBY) has announced that its antiviral drug Xofluza (baloxavir marboxil) has...
J&J’s Rybrevant Secures FDA Approval for EGFR/c-MET Non-Small Cell Lung Cancer Treatment
Johnson & Johnson (J&J; NYSE: JNJ)has announced that the US Food and Drug Administration (FDA)...
Beijing’s Apollobio Receives NMPA Approval for HPV Therapeutic Vaccine VGX-3100
Beijing’s Apollobio, has announced that the National Medical Products Administration (NMPA) has granted market approval...
Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study
China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its...
Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has...
Jiangsu Hengrui Pharmaceuticals’ SHR-1701 Combo Therapy for Gastric Cancer Accepted for Review by China’s NMPA
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
JiCui Cell Therapy Forms Partnership with Fosun Kite to Advance Bispecific CAR-T Cell Therapy Industrialization
JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute...
Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D...
CSPC Pharmaceutical Group Appoints Dr. Liu Yongjun as Group CEO and Global R&D President
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Sinopharm Holding Appoints New Chairman and President Following Leadership Changes
Sinopharm Holding (HKG: 1099) has announced significant changes in its leadership with the approval of...
China’s NMPA Releases Standards for Brain-Computer Interface Medical Devices
The National Medical Products Administration (NMPA) in China has issued a notification confirming the establishment...
Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first...
Ocumension Therapeutics’ Zerviate Receives Marketing Approval in China for Allergic Conjunctivitis Treatment
Ocumension Therapeutics (HKG: 1477), a leading ophthalmology specialist in China, has announced that its histamine...
Organon Inks Deal to Acquire Dermavant, Bolstering Dermatology Portfolio with Vtama Cream
US healthcare company Organon (NYSE: OGN) has announced a definitive agreement to acquire Dermavant, a...